Vivos closes $6M+stock acquisition of Sleep Center of Nevada; secures $11M+ financing

Vivos Therapeutics, Inc.

Acquired SCN for $6M cash + $1.5M in stock (607,287 shares) + assumption of liabilities; up to $1.5M earn-out in stock.
Senior secured loan of $8.25M from Streeterville Capital (9% interest, 18-month maturity) netted $7.5M to Vivos.
PIPE from New Seneca affiliate: 828K shares, pre-funded warrant for 725K shares, and 5-yr warrant for 2.33M shares at $2.23; total gross ~$3.755M.
SCN sees ~3,000 new patients/month, annual high-seven-figure revenue; 90% test positive for OSA; Vivos expects to add diagnostic/appliance revenue over 12-18 months.
Board-certified sleep specialists Dr. Prabhu Rachakonda and Dr. Tara Rachakonda join Vivos; continue practice management.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.